PL3526244T3 - Peptydy pochodzące z propeptydu ntsr3 i ich zastosowanie w leczeniu depresji - Google Patents

Peptydy pochodzące z propeptydu ntsr3 i ich zastosowanie w leczeniu depresji

Info

Publication number
PL3526244T3
PL3526244T3 PL17794365.1T PL17794365T PL3526244T3 PL 3526244 T3 PL3526244 T3 PL 3526244T3 PL 17794365 T PL17794365 T PL 17794365T PL 3526244 T3 PL3526244 T3 PL 3526244T3
Authority
PL
Poland
Prior art keywords
ntsr3
propeptide
depression
treatment
peptides derived
Prior art date
Application number
PL17794365.1T
Other languages
English (en)
Inventor
Jean Mazella
Marc Borsotto
Catherine Heurteaux
Alaeddine DJILLANI
Sébastien MORENO
Mariel PIETRI
Original Assignee
Centre National De La Recherche Scientifique
Université Côte d'Azur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR1754127A external-priority patent/FR3057266B1/fr
Application filed by Centre National De La Recherche Scientifique, Université Côte d'Azur filed Critical Centre National De La Recherche Scientifique
Publication of PL3526244T3 publication Critical patent/PL3526244T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Obesity (AREA)
PL17794365.1T 2016-10-11 2017-10-11 Peptydy pochodzące z propeptydu ntsr3 i ich zastosowanie w leczeniu depresji PL3526244T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR1659781A FR3057267A1 (fr) 2016-10-11 2016-10-11 Procede de diagnostic/determination de l'efficacite de traitement de la depression
FR1752162A FR3057268B1 (fr) 2016-10-11 2017-03-16 Procede de diagnostic/determination de l'efficacite de traitement de la depression
FR1754127A FR3057266B1 (fr) 2016-10-11 2017-05-11 Peptides derives du propeptide ntsr3 et leur utilisation dans le traitement de la depression
PCT/FR2017/052788 WO2018069641A1 (fr) 2016-10-11 2017-10-11 Peptides dérivés du propeptide ntsr3 et leur utilisation dans le traitement de la dépression

Publications (1)

Publication Number Publication Date
PL3526244T3 true PL3526244T3 (pl) 2024-07-01

Family

ID=59297081

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17794365.1T PL3526244T3 (pl) 2016-10-11 2017-10-11 Peptydy pochodzące z propeptydu ntsr3 i ich zastosowanie w leczeniu depresji

Country Status (12)

Country Link
US (2) US20200190172A1 (pl)
EP (2) EP3526244B1 (pl)
JP (2) JP7034151B2 (pl)
CA (1) CA3040054A1 (pl)
DK (1) DK3526244T5 (pl)
ES (1) ES2965080T3 (pl)
FI (1) FI3526244T3 (pl)
FR (3) FR3057267A1 (pl)
HR (1) HRP20231567T1 (pl)
PL (1) PL3526244T3 (pl)
PT (1) PT3526244T (pl)
WO (2) WO2018069640A2 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114544821B (zh) * 2020-11-24 2023-10-24 重庆医科大学 检测血浆中磷脂酰乙醇胺（36:4）的试剂在制备抑郁症检测试剂盒中的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE545429T1 (de) 2002-12-20 2012-03-15 Lundbeck & Co As H Modulation der neurotrophinaktivität;screeningsverfahren
EP2077278A1 (fr) 2007-12-21 2009-07-08 Centre National de la Recherche Scientifique (CNRS) Peptide dérivé du récepteur 3 de la neurotensine et utilisation dans le traitemement de maladies psychiatriques
US20120322060A1 (en) * 2011-04-13 2012-12-20 Centre National De Le Recherche Scientifique - Cnrs - Diagnosis and monitoring treatment of psychiatric diseases with spadin and related methods
JP6640725B2 (ja) 2014-01-27 2020-02-05 セントレ ナショナル デ ラ レチャーチェ シャーティフィック ｓｐａｄｉｎのレトロ−インベルソ類似体は増大された抗うつ作用を示す
CN105980858A (zh) * 2014-02-12 2016-09-28 H.隆德贝克有限公司 分拣蛋白作为针对情感/心境障碍的生物标记的用途

Also Published As

Publication number Publication date
EP3526243A2 (fr) 2019-08-21
WO2018069640A3 (fr) 2018-06-07
JP7034151B2 (ja) 2022-03-11
WO2018069640A2 (fr) 2018-04-19
US11220527B2 (en) 2022-01-11
HRP20231567T1 (hr) 2024-03-15
CA3039273A1 (fr) 2018-04-19
DK3526244T5 (da) 2024-09-02
JP2019534259A (ja) 2019-11-28
PT3526244T (pt) 2023-12-11
DK3526244T3 (da) 2023-12-11
ES2965080T3 (es) 2024-04-11
WO2018069641A1 (fr) 2018-04-19
US20190270771A1 (en) 2019-09-05
FR3057268A1 (fr) 2018-04-13
FR3057268B1 (fr) 2021-06-04
US20200190172A1 (en) 2020-06-18
EP3526244B1 (fr) 2023-09-06
JP2020502995A (ja) 2020-01-30
EP3526244A1 (fr) 2019-08-21
FR3057267A1 (fr) 2018-04-13
FR3068697A1 (fr) 2019-01-11
FI3526244T3 (en) 2023-12-11
CA3040054A1 (fr) 2018-04-19

Similar Documents

Publication Publication Date Title
IL273432A (en) Protein compounds and their uses
IL264970A (en) Anti-tim-3 antibodies and their use
IL290754A (en) Use of pyridofidine to treat anxiety and depression
GB201411496D0 (en) Use of 7-Oh-Cannabidiol (7-Oh-CBD) and/or 7-Oh-Cannabidvarin (7-Oh-CBDV) in the treatment of epilepsy
IL255577B (en) Binding materials - tigit and their uses
GB201519858D0 (en) Therapeutic combinations comprising anti-CD73 antibodies and uses thereof
IL264813B (en) 2-oxo-imidazopyridines and their use
PL3197472T3 (pl) Rekombinowane białka wolne od phe do stosowania w leczeniu fenyloketonurii
IL256515A (en) Therapeutic peptides and methods of use thereof
SMT202300299T1 (it) Nuovi polipeptidi e relativi usi medici
SG11201708624YA (en) Therapeutic antibodies and uses thereof
ZA201704726B (en) Peptides and their use in the treatment of skin
IL264962A (en) Antibodies against vegf-a and against ang2 and their uses
ZA201905851B (en) Peptides and methods for the treatment of diabetes
SMT202500469T1 (it) Combinazione farmaceutica comprendente ponesimod e suo utilizzo nel trattamento della sclerosi multipla
IL259096A (en) Peptides and methods of treating endometriosis using the same
IL272050A (en) Synthetic proteins and their therapeutic uses
PT3177599T (pt) Análogos fumarato e utilizações dos mesmos no tratamento de uma doença autoimune ou uma doença inflamatória
ZA201904386B (en) S-arrestin peptides and therapeutic uses thereof
ZA201901942B (en) Nnif and nnif-related peptides and related methods
PT3331853T (pt) Amida selecionada de ácido γ-hidroxibutírico e suas utilizações no tratamento de abuso de álcool
PL3262069T3 (pl) Zastosowanie przeciwciał i antagonistów skierowanych przeciwko LRG1 w leczeniu
EP3110453A4 (en) Tmem100 peptides and variants thereof and their use in treating or preventing diseases or conditions
PL3327201T3 (pl) Pojemnik i jego zastosowanie
PT3526244T (pt) Péptidos derivados do propéptido ntsr3 e a sua utilização no tratamento da depressão